Published in Science on November 13, 2008
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet (2009) 12.08
A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer (2011) 11.33
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet (2010) 7.96
Epigenetic modifications and human disease. Nat Biotechnol (2010) 7.29
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer (2013) 6.13
Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev (2010) 5.83
MicroRNAs--the micro steering wheel of tumour metastases. Nat Rev Cancer (2009) 5.47
The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer (2012) 4.97
The microcosmos of cancer. Nature (2012) 4.50
Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer (2009) 4.40
Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell (2010) 4.18
Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell (2012) 3.65
MicroRNAs in cancer. Annu Rev Pathol (2013) 3.50
Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proc Natl Acad Sci U S A (2012) 3.22
Epigenetic modifications as therapeutic targets. Nat Biotechnol (2010) 3.16
Interplay between the cancer genome and epigenome. Cell (2013) 3.05
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood (2010) 2.71
Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol (2010) 2.64
Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64
Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One (2010) 2.55
Mir-214-dependent regulation of the polycomb protein Ezh2 in skeletal muscle and embryonic stem cells. Mol Cell (2009) 2.47
Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev (2009) 2.40
Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat Cell Biol (2010) 2.38
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
The role of EZH2 in tumour progression. Br J Cancer (2011) 2.33
Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood (2011) 2.09
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med (2016) 2.04
Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02
microRNA-101 is a potent inhibitor of autophagy. EMBO J (2011) 2.00
Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis (2010) 1.98
miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget (2010) 1.92
Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol (2010) 1.92
MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Mol Cancer (2010) 1.87
Genome-wide DNA methylation profiling reveals novel epigenetically regulated genes and non-coding RNAs in human testicular cancer. Br J Cancer (2010) 1.86
Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell (2011) 1.86
Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res (2011) 1.80
Genome-wide functional screening of miR-23b as a pleiotropic modulator suppressing cancer metastasis. Nat Commun (2011) 1.80
miRNA control of tumor cell invasion and metastasis. Int J Cancer (2010) 1.79
Myocardial AKT: the omnipresent nexus. Physiol Rev (2011) 1.76
Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol (2013) 1.75
Targeting DNA-PKcs and ATM with miR-101 sensitizes tumors to radiation. PLoS One (2010) 1.70
Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci (2010) 1.61
Comprehensive survey of human brain microRNA by deep sequencing. BMC Genomics (2010) 1.59
Identification of miRs-143 and -145 that is associated with bone metastasis of prostate cancer and involved in the regulation of EMT. PLoS One (2011) 1.55
MYC and Prostate Cancer. Genes Cancer (2010) 1.54
Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet (2013) 1.53
Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget (2011) 1.52
FGF-2 regulates cell proliferation, migration, and angiogenesis through an NDY1/KDM2B-miR-101-EZH2 pathway. Mol Cell (2011) 1.49
EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS One (2011) 1.49
EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res (2011) 1.46
Silencing of long noncoding RNA MALAT1 by miR-101 and miR-217 inhibits proliferation, migration, and invasion of esophageal squamous cell carcinoma cells. J Biol Chem (2014) 1.44
Development of the human cancer microRNA network. Silence (2010) 1.43
MicroRNAs: critical mediators of differentiation, development and disease. Swiss Med Wkly (2009) 1.43
MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res (2011) 1.39
Targeting of microRNA-142-3p in dendritic cells regulates endotoxin-induced mortality. Blood (2011) 1.39
Cyclin-dependent kinase 1 (CDK1)-mediated phosphorylation of enhancer of zeste 2 (Ezh2) regulates its stability. J Biol Chem (2011) 1.37
Tumour-suppressor microRNAs let-7 and mir-101 target the proto-oncogene MYCN and inhibit cell proliferation in MYCN-amplified neuroblastoma. Br J Cancer (2011) 1.37
Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget (2012) 1.36
ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS One (2010) 1.35
Epigenetic mechanisms in inflammation. J Dent Res (2011) 1.35
Decreased microRNA-214 levels in breast cancer cells coincides with increased cell proliferation, invasion and accumulation of the Polycomb Ezh2 methyltransferase. Carcinogenesis (2011) 1.35
Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell (2012) 1.34
Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM. PLoS One (2012) 1.33
The tumor suppressor gene rap1GAP is silenced by miR-101-mediated EZH2 overexpression in invasive squamous cell carcinoma. Oncogene (2011) 1.32
microRNA and cancer. AAPS J (2010) 1.32
Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev (2011) 1.32
BRCA1 is a negative modulator of the PRC2 complex. EMBO J (2013) 1.31
Genomic loss of tumor suppressor miRNA-204 promotes cancer cell migration and invasion by activating AKT/mTOR/Rac1 signaling and actin reorganization. PLoS One (2012) 1.31
Upregulation of MircoRNA-370 induces proliferation in human prostate cancer cells by downregulating the transcription factor FOXO1. PLoS One (2012) 1.30
Curating the innate immunity interactome. BMC Syst Biol (2010) 1.30
EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Mol Cancer Res (2011) 1.30
An extensive network of TET2-targeting MicroRNAs regulates malignant hematopoiesis. Cell Rep (2013) 1.29
Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors. Nat Rev Urol (2010) 1.28
EZH2 in normal and malignant hematopoiesis. Leukemia (2013) 1.28
The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol (2010) 1.28
Polycomb group protein enhancer of zeste 2 is an oncogene that promotes the neoplastic transformation of a benign prostatic epithelial cell line. Mol Cancer Res (2009) 1.27
Regulation and Role of EZH2 in Cancer. Cancer Res Treat (2014) 1.27
The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectal cancer. PLoS One (2012) 1.26
The redox basis of epigenetic modifications: from mechanisms to functional consequences. Antioxid Redox Signal (2011) 1.24
The roles of EZH2 in cell lineage commitment. Am J Transl Res (2011) 1.24
Androgens suppress EZH2 expression via retinoblastoma (RB) and p130-dependent pathways: a potential mechanism of androgen-refractory progression of prostate cancer. Endocrinology (2010) 1.22
MicroRNA Deregulations in Head and Neck Squamous Cell Carcinomas. J Oral Maxillofac Res (2013) 1.22
MicroRNA-101 downregulates Alzheimer's amyloid-β precursor protein levels in human cell cultures and is differentially expressed. Biochem Biophys Res Commun (2010) 1.21
Enforced expression of miR-101 inhibits prostate cancer cell growth by modulating the COX-2 pathway in vivo. Cancer Prev Res (Phila) (2011) 1.21
EZH2: not EZHY (easy) to deal. Mol Cancer Res (2014) 1.20
Epigenetic alteration and microRNA dysregulation in cancer. Front Genet (2013) 1.19
The role of sarcosine metabolism in prostate cancer progression. Neoplasia (2013) 1.18
miRNA Biomarkers in Breast Cancer Detection and Management. J Cancer (2011) 1.18
MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1. PLoS One (2012) 1.17
Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. Nat Commun (2014) 1.17
Identification of microRNA-98 as a therapeutic target inhibiting prostate cancer growth and a biomarker induced by vitamin D. J Biol Chem (2012) 1.16
Phosphorylation of EZH2 by CDK1 and CDK2: a possible regulatory mechanism of transmission of the H3K27me3 epigenetic mark through cell divisions. Cell Cycle (2011) 1.15
Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma. Proc Natl Acad Sci U S A (2010) 1.15
Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. Nat Immunol (2015) 1.14
Dietary omega-3 polyunsaturated fatty acids suppress expression of EZH2 in breast cancer cells. Carcinogenesis (2009) 1.14
MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer. Oncogene (2012) 1.13
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
Prediction of mammalian microRNA targets. Cell (2003) 53.70
Combinatorial microRNA target predictions. Nat Genet (2005) 50.48
Human MicroRNA targets. PLoS Biol (2004) 34.51
Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56
Control of developmental regulators by Polycomb in human embryonic stem cells. Cell (2006) 28.21
Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature (2006) 25.90
Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (2002) 24.31
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Connecting microRNA genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell (2008) 16.38
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev (2002) 13.08
Role of histone H3 lysine 27 methylation in X inactivation. Science (2003) 9.85
EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J (2003) 9.55
Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J (2004) 7.32
A guide through present computational approaches for the identification of mammalian microRNA targets. Nat Methods (2006) 7.00
Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell (2007) 4.43
EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol (2005) 4.24
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A (2005) 3.24
Consequences of the depletion of zygotic and embryonic enhancer of zeste 2 during preimplantation mouse development. Development (2003) 2.91
MicroInspector: a web tool for detection of miRNA binding sites in an RNA sequence. Nucleic Acids Res (2005) 2.87
Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer. Cancer Sci (2006) 2.19
The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene (2005) 1.73
Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med (2005) 1.67
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells. Mol Cancer Ther (2006) 1.56
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
The Sorghum bicolor genome and the diversification of grasses. Nature (2009) 14.62
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A (2003) 13.68
ProbeMatch: rapid alignment of oligonucleotides to genome allowing both gaps and mismatches. Bioinformatics (2009) 13.34
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev (2007) 13.05
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Transcriptome sequencing to detect gene fusions in cancer. Nature (2009) 11.63
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (2007) 10.74
Human protein reference database as a discovery resource for proteomics. Nucleic Acids Res (2004) 9.99
TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88
Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A (2004) 9.42
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature (2012) 8.03
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
The emergence of lncRNAs in cancer biology. Cancer Discov (2011) 6.32
Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell (2012) 6.09
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
The transcriptional network that controls growth arrest and differentiation in a human myeloid leukemia cell line. Nat Genet (2009) 6.02
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Whole-genome cartography of estrogen receptor alpha binding sites. PLoS Genet (2007) 5.85
Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med (2011) 5.82
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A (2009) 5.30
EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia (2008) 5.22
miR-24 Inhibits cell proliferation by targeting E2F2, MYC, and other cell-cycle genes via binding to "seedless" 3'UTR microRNA recognition elements. Mol Cell (2009) 5.22
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res (2006) 4.99
Fusion transcripts and transcribed retrotransposed loci discovered through comprehensive transcriptome analysis using Paired-End diTags (PETs). Genome Res (2007) 4.99